Open AccessJournal Article
Long-term survival.
Cho Yw,Terasaki Pi +1 more
TLDR
In transplants performed between 1971 and 1986, first cadaver donor grafts had a half-life ranging from 6.6 to 7.5 years in the period after the first year, and for patients receiving kidneys with no HLA-A,B mismatches, the average half- life was 10.1 years.Abstract:
1. In transplants performed between 1971 and 1986, first cadaver donor grafts had a half-life ranging from 6.6 to 7.5 years in the period after the first year. Second cadaver donor grafts had a half-life of 5.1 to 6.5 years. Parental donor grafts had a half-life of 9.3 to 11.8 years, whereas HLA identical sibling donor transplants had a half-life of 19.1 to 26.5 years. Siblings with no haplotype in common had an average half-life of 8.7 years. 2. Between 1971 and 1984, white recipients had an average half-life of 7.7 years, which increased to 9.3 years in 1985-1986. Black recipients' half-life decreased from 5.4 years in 1975-1976 to 3.5 years in 1985-1986. The reason for this decrease is not apparent. 3. The half-life of transplants of different recipient ages did not vary significantly. The average half-life during this period of study was 7.4 years for those younger than 21 years of age, 8.2 years for recipients 21 to 50 and 6.7 years for those older than 50. 4. In the early data, there was some evidence that the half-life of kidneys with cold ischemia below 13 hours was superior. However, in the latest period (between 1983 and 1986) the average half-life was 7.6 years for CIT below 13 hours, 7.2 years for those with 13 to 24 hours and 6.4 years for more than 24 hours. 5. For patients receiving kidneys with no HLA-A,B mismatches, the average half-life was 10.1 years. Those with A,B mismatches had a half-life of 6.7 years, and for those with no A,B antigens in common, the average half-life was 6 years. 6. In the period after 1981, the average half-life of patients with no A,B,DR mismatches was 9.1 years compared with 6.5 years for those with A,B,DR mismatches and 5.4 years for those with no A,B,DR antigens in common.read more
Citations
More filters
Journal ArticleDOI
Prognostic factors and classification in multiple myeloma.
TL;DR: In a series of 220 patients with multiple myeloma, univariate analysis showed that nine parameters had a significant adverse effect on survival, and the best combination of disease characteristics selected by means of the Cox regression proportional hazards method were performance status and creatinine levels.
Journal ArticleDOI
High-intensity focused ultrasound ablation: An effective bridging therapy for hepatocellular carcinoma patients
Tan To Cheung,Sheung Tat Fan,See Ching Chan,Kenneth S. H. Chok,Ferdinand S. K. Chu,Caroline R. Jenkins,Regina Cheuk-Lam Lo,James Fung,Albert C. Y. Chan,William W. Sharr,Simon H Y Tsang,Wing Chiu Dai,Ronnie T.P. Poon,Chung Mau Lo +13 more
TL;DR: HIFU ablation is safe and effective in the treatment of HCC for patients with advanced cirrhosis and may reduce the drop-out rate of liver transplant candidate.
Journal ArticleDOI
Coronary artery bypass graft surgery in dialysis patients
TL;DR: Coronary artery bypass graft surgery can be performed with increased but acceptable morbidity and mortality in chronic dialysis patients and results in considerable improvement in symptoms and functional status.
Journal ArticleDOI
Pre-operative pulmonary assessment for patients with hip fracture
TL;DR: This review aims to provide evidence-based recommendations for preoperative assessment and perioperative strategies to reduce the risk of pulmonary complications after hip fracture surgery.
Journal ArticleDOI
Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism
Andreas Schäfer,Daniela Fraccarollo,Piet W.L. Tas,Isabel Schmidt,Georg Ertl,Johann Bauersachs +5 more
TL;DR: This study systematically investigated the effect of angiotensin II (AT1)‐ receptor blockade on vascular superoxide (O2−) production and endothelial dysfunction in congestive heart failure.